We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Iloprost Therapy in Patients With Critical Limb Ischemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01458041
First Posted: October 24, 2011
Last Update Posted: March 2, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bayer
October 10, 2011
October 24, 2011
March 2, 2015
August 2011
May 2014   (Final data collection date for primary outcome measure)
Change of limb pain at rest assessed by visual analogue scale [ Time Frame: At baseline, at the end of iloprost treatment, at follow-up visits ( month 3, 6, 12) ]
Pain relief will be defined as complete relief of pain while off analgesics
Same as current
Complete list of historical versions of study NCT01458041 on ClinicalTrials.gov Archive Site
  • Incidence of ulcer healing [ Time Frame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12) ]
  • Collection of interventional / surgical procedures including 1) Rate of revascularization procedures; 2) Minor amputations; 3) Frequency and height of major amputations [ Time Frame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12) ]
  • Mortality and/or severe cardiovascular events (AMI, stroke) [ Time Frame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12) ]
  • Hemodynamic measurements: peripheral arterial blood flow and pressure on ankle / hallux level by Doppler scanner [ Time Frame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12) ]
  • Changes of transcutaneously measured tissue oxygen tension values [ Time Frame: at baseline, at the end of iloprost treatment and at follow-up visits ( month 3, 6, 12) ]
Same as current
Not Provided
Not Provided
 
Iloprost Therapy in Patients With Critical Limb Ischemia
Iloprost Therapy in Patients With Critical Limb Ischemia: Evaluation of Efficacy and Safety
Monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Hospitalized patients
Peripheral Arterial Disease
Drug: Iloprost (Ilomedin, BAYQ6256)
Prescription and treatment of Iloprost will be decided by physicians
Group 1
Intervention: Drug: Iloprost (Ilomedin, BAYQ6256)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
126
December 2014
May 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who fulfill the internationally defined criteria of critical limb ischemia;
  • Patients who are not eligible for vascular surgery or angioplasty interventions and
  • Patients who are treated with iloprost infusion.
  • The treating physician has decided iloprost treatment before study enrollment.

Exclusion Criteria:

  • Exclusion criteria are in accordance with the Summary of Product Characteristics of Ilomedin.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Hungary
 
 
NCT01458041
15439
VE1011HU ( Other Identifier: Company Internal )
No
Not Provided
Not Provided
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
February 2015